Bristol-Myers Squibb

FDA nod helps BMS' Opdivo even the head-and-neck cancer score with Merck's Keytruda

Bristol-Myers' Opdivo nets the first PhIII gastric cancer win for checkpoint inhibitors

With pharma lobbying hard, California's contentious Prop 61 is now a toss-up, poll shows

Hot immuno-oncology combos can trigger rare but fatal heart damage: NEJM

Roche's Tecentriq scores lung cancer nod, setting up 3-way battle with Merck, BMS

Japan seeks hefty cut to blockbuster Opdivo price as officials pull back the reins on health spending